Table 1.

Patient demographics.

Age in years, median (range)	58 (20–74)
Sex, no. (%)
Male	32 (52.5)
Female	29 (47.5)
Diagnosis, no. (%) AML (according to WHO 2022) with defining genetic abnormalities - AML, myelodysplasia-related - AML with NPM1 mutation - AML with RUNX1::RUNX1T1 fusion - AML with CEBPA mutation - AML with KMT2A rearrangement - AML with CBFB::MYH11 fusion myeloid neoplasm post-cytotoxic therapy defined by differentiation - acute myelomonocytic leukemia - AML with minimal differentiation - acute basophilic leukemia - acute monocytic leukemia	40 (65.6) 31 (50.8) 17 (27.9) 7 (11.5) 3 (4.9) 2 (3.3) 1 (1.6) 1 (1.6) 2 (3.3) 7 (11.5) 3 (4.9) 2 (3.3) 1 (1.6) 1 (1.6)
MDS (according to WHO 2022) with bi-allelic TP53 inactivation with increased blasts 1 with increased blasts 2 MDS with low blasts	18 (29.5) 6 (9.8) 6 (9.8) 5 (8.2) 1 (1.6)
CMML CMML0 CMML1	2 (3.3) 1 (1.6) 1 (1.6)
CML (in blast crisis)	1 (1.6)
Risk stratification according to genetics, no. (%)
High-risk	45 (73.8)
Intermediate	12 (19.7)
Favorable	4 (6.6)
HCT-CI, no. (%)
0	21 (34.4)
1–2	19 (31.1)
≥3	19 (31.1)
Unknown	2 (3.3)
Disease status at transplant, no. (%)
Relapsed/refractory	41 (67.2)
Untreated disease	19 (31.1)
CR	1 (1.6)
Number of transplant(s), no. (%)
First	58 (95.1)
Second	3 (4.9)
Conditioning regimen, no. (%)
FLAMSA + melphalan (100–200 mg/m2)	29 (47.5)
FLAMSA + treosulfan (30 g/m2)	22 (36.1)
FLAMSA + Cy 60 mg/kg + TBI 4 Gy	9 (14.8)
FLAMSA + Cy 60 mg/kg + TBI 8 Gy	1 (1.6)
FLAMSA + TBI 4 Gy	1 (1.6)
Donor, no. (%)
Matched unrelated donor (MUD)	32 (52.5)
Matched related donor (MRD)	12 (19.7)
Haploidentical	10 (16.4)
Mismatched unrelated donor 9/10 (MMUD)	7 (11.5)
GVHD prophylaxis, no. (%)
Antithymocyte globulin 3 × 5 mg/kg BW	5 (8.2)
Antithymocyte globulin 3 × 10 mg/kg BW	30 (49.2)
Antithymocyte globulin 3 × 20 mg/kg BW	7 (11.5)
Post-Transplant cyclophosphamide 50 mg/kg BW	15 (24.6)
None	4 (6.6)